All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-08-24.
From the record
Anixa Biosciences, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2017-08-24) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-4.4% a year over 7 filed years; profitable in 0 of 7.
From the record
Anixa Biosciences, Inc.'s 7 filed years say what it did: revenue went from $300 thousand in fiscal 2016 to $210 thousand in fiscal 2024, down 4.4% a year; it rose in 4 of 6 years; the deepest fall was 81% from fiscal 2018 to fiscal 2023; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Anixa Biosciences, Inc.'s shareholder treatment is put at 7.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 21% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -72%: lost 72¢ per shareholder dollar. Leverage 6%: owes 6¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-10-31, Anixa Biosciences, Inc. lost about 72 cents for every dollar of shareholders' money. Leverage: it owed about 6 cents per dollar of assets, and net share issuance: its share count grew 1.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 21% of 315 in its family.
From the record
Anixa Biosciences, Inc.'s standing among 315 graded names in its industry family: revenue of $210 thousand in fiscal 2024 ranks in the bottom 11% by size; revenue growth of -3.4% a year over the last 3 filed years ranks in the bottom 32% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 9% of 315 in its family for leadership; chief executive since 2017.
From the record
Anixa Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kumar, Amit (Chief Executive Officer, as filed), filing under that title since 2017-09-08, 9.2 years (top 19% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 10.2 years (top 8%); no officer or director change was reported on Form 8-K since 2023-11-13, against the 5 people in charge now (top 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 2.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Anixa Biosciences, Inc.'s room to expand is put at 2.1 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 22% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
bottom 47% of 306 in its family for growth drivers.
From the record
Anixa Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2024: revenue grew -3.4% a year over the last three filed years against -4.4% over all 7, speeding up (top 27% of its family); the newest year grew 0% (bottom 38%); research spending grew -8.9% a year (bottom 32%); capital spending grew -19.4% a year (bottom 45%) (its annual reports). Anixa Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 6.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Anixa Biosciences, Inc.'s expectations vs reality is put at 6.2 of 10 with a confidence of 35 of 100, because read from one part only, revenue against the prior three years' pace, which ranks in the top 38% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made